|
1. Biologie
|
|
|
|
Mark Zuckerberg Is Funding a Facebook for Human Cells [MIT Technology Review]
|
|
|
|
|
|
What
scientists want to do now is to inspect tens of millions of human cells
for their molecular signatures and also locate each type in the body.
That sort of map could be useful to scientists or drugmakers, who might,
for instance, look up which cells a new drug is likely to effect.
Cataloging how the immune system changes and adapts to fight tumors
could be the source of the next insights for cancer treatments.
|
|
|
|
|
|
|
3.1 Tabac
|
|
|
|
|
3.1.1 Tabac - e-cigs
|
|
|
|
3.2 Prévention - Obésité
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.11 Dép., diag. & prono. - Ovaire
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
Genetic testing fumbles, revealing ‘dark side’ of precision medicine [STAT]
|
|
|
|
|
|
Enthusiasm
for precision medicine, from the White House down to everyday
physicians, is at an all-time high. But serious problems with the
databases used to interpret patients’ genetic profiles can lead to
“inappropriate treatment” with “devastating consequences,” researchers
at the Mayo Clinic warned on Monday.
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5. Traitements
|
|
|
A look at scientists’ efforts to conquer a deadly brain tumor [Stanford Medicine]
|
|
|
|
|
|
There’s
a fascinating new story in Scientific American about how
precision-medicine techniques are helping scientists crack the mysteries
of the deadliest brain tumor. The tumor, a form of pediatric cancer
called diffuse intrinsic pontine glioma, is truly devastating: It has a
one-percent survival rate five years after diagnosis, and that figure
hasn’t budged in 40 years.
|
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
In defense of data sharing, but done in the right way [STAT]
|
|
|
|
|
|
What
we have seen, and what researchers we’ve spoken to have said, is that
understanding clinical trial data sets is not easy. A great deal of time
can be spent getting the data straight. No matter how carefully data
are curated, there are always questions. If someone wants to use a data
set, they need to understand it and use it wisely and responsibly.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
Celgene May Be Ready to Lap Bristol [Bloomberg]
|
|
|
|
|
|
The
distinction between big biotech and big pharma has grown increasingly
moot as several biotechs have gotten larger than their much older peers.
That might soon happen again, with biotech giant Celgene Corp.
approaching the size of big-pharma stalwart Bristol-Myers Squibb Co.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
|
FDA approves clinical trial of Cuban lung cancer vaccine [Pharmafile]
|
|
|
|
|
|
The
clinical trial will be held at the Roswell Park Cancer Institute in
Buffalo, with 60 to 90 patients who had previously been treated for
advanced NSCLC given the vaccine. The vaccine, named CimaVax, targets
the epidermal growth factor receptor, which is ‘overexpressed’ in
approximately 40% to 80% of NSCLCs.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
NICE rejects Merck’s Erbitux [Pharma Times]
|
|
|
|
|
|
"This
decision not to recommend cetuximab as an option for treating mouth
cancer will be disappointing for some patients. However we need to make
sure the NHS makes the most of its resources by only funding treatments
that are both clinically effective and represent good value for money,"
said Professor Carole Longson, director of the health technology
evaluation centre at NICE.
|
|
|
|
|
|
|
5.9 AACR
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
World Cancer Declaration Progress Report 2016 [UICC]
|
|
|
|
|
|
Whilst
many UICC members are contributing to the development of national
cancer and NCD plans – the Report highlights that many of these are not
publically available or are not being implemented due to lack of
funding, or expertise for scale up.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.4 Médico-éco
|
|
|
|
|
6.6 Publications
|
|
|
Publisher Retracts Dozens of Studies [The Scientist]
|
|
|
|
|
|
Springer
Nature, the company behind both subsidiary publishers, issued the mass
retraction notice upon discovering that some of the now-pulled papers’
authors had manipulated the peer review process, and that some of the
reports contained plagiarism.
|
|
|
|
|
|
|
|
6.8 Communication
|
|
|
Early report card on quality of FDA news releases: C at best [HealthNewsReview]
|
|
|
|
|
|
Speaking
hypothetically here, a release shouldn’t simply state that, say, a new
drug cut heart attack risk in half. Instead, state that of 100 people
divided equally into a control and intervention group, 2 had heart
attacks in the control group, and 1 had a heart attack in the
intervention group (a 50% relative risk reduction that sounds very
impressive when framed that way, but a 1% absolute risk reduction for
the people in the study).
|
|
|
|
|
|
|
6.9 Controverses
|
|
|